MGC Pharmaceuticals Limited Director/PDMR Shareholding (9127Z)
May 18 2023 - 7:00AM
UK Regulatory
TIDMMXC
RNS Number : 9127Z
MGC Pharmaceuticals Limited
18 May 2023
MGC Pharmaceuticals Ltd.
PDMR Notification
18 May 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes
to advise that the following Persons Discharging Managerial
Responsibilities (PDMR) have dealt with shares in MGC Pharma, and
this notification is made in accordance the UK Market Abuse
Regulations.
1 Details of the person discharging managerial responsibilities/person
closely associated
(a) Name Nicole Godresse
--------------------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
(a) Position Global Chief Sales Officer MGC
Medical
--------------------------------------- -----------------------------------
(b) Initial notification/amendment Initial
--------------------------------------- -----------------------------------
(c) If amendment: reason n/a
--------------------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
Full name of entity MGC Pharmaceuticals Limited
--------------------------------------- -----------------------------------
Legal Entity Identifier 213800HRE3FQJ6RK4H10
Code
--------------------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
(a) Description of the financial Fully Paid Ordinary Shares
instrument, type of
instrument
--------------------------------------- -----------------------------------
(b) Identification Code AU000000MXC6
(ISIN)
--------------------------------------- -----------------------------------
(c) Nature of transaction Disposal of shares
--------------------------------------- -----------------------------------
(d) Currency Price Volume Total
------------------ ------------------- ------------- --------------------
AUD $0.007 876,636 $6,136
------------------------ ------------------- ------------- --------------------
Aggregated information
----------------------------------------------------------------------------
AUD $0.007 876,636 $6,136
------------------------ ------------------- ------------- --------------------
(e) Date of transaction 2023-05-16
--------------------------------------- -----------------------------------
(f) Place of transaction Australian Stock Exchange
--------------------------------------- -----------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
(a) Name Amir Polak
--------------------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
(a) Position Chief Pharmaceutical Development
Officer
--------------------------------------- -----------------------------------
(b) Initial notification/amendment Initial
--------------------------------------- -----------------------------------
(c) If amendment: reason n/a
--------------------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
Full name of entity MGC Pharmaceuticals Limited
--------------------------------------- -----------------------------------
Legal Entity Identifier 213800HRE3FQJ6RK4H10
Code
--------------------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
(a) Description of the financial Fully Paid Ordinary Shares
instrument, type of
instrument
--------------------------------------- -----------------------------------
(b) Identification Code AU000000MXC6
(ISIN)
--------------------------------------- -----------------------------------
(c) Nature of transaction Disposal of shares
--------------------------------------- -----------------------------------
(d) Currency Price Volume Total
------------------ ------------------- ------------- --------------------
AUD $0.007 500,000 $3,500
------------------------ ------------------- ------------- --------------------
Aggregated information
----------------------------------------------------------------------------
AUD $0.007 500,000 $3,500
------------------------ ------------------- ------------- --------------------
(e) Date of transaction 2023-05-17
--------------------------------------- -----------------------------------
(f) Place of transaction Australian Stock Exchange
--------------------------------------- -----------------------------------
--Ends-
Authorised for release by the Managing Director, for further
information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Arron Canicais / Rowan Harland
CEO & Managing Director Joint Company Secretaries
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.co.uk info@mgcpharma.co.uk
UK PR Advisors UK Brokers
Tavistock Peterhouse Capital
Charles Vivian / Tim Pearson Charles Goodfellow / Lucy Williams
+44 207 920 3150 +44 207 469 0930
mgcpharma@tavistock.co.uk cg@peterhousecap.com / lw@peterhousecap.com
UK Financial and Corporate Advisor
SW4 Partners
Rupert Fane / Nilesh Patel
rupert@sw4partners.com / nilesh@sw4partners.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBGGDULUBDGXI
(END) Dow Jones Newswires
May 18, 2023 07:00 ET (11:00 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Oct 2023 to Oct 2024